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Abstract Activin receptor-like kinase 1 (ALK1, encoded
by the gene ACVRL1) is a type I BMP/TGF-b receptor that
mediates signalling in endothelial cells via phosphorylation
of SMAD1/5/8. During angiogenesis, sprouting endothelial
cells specialise into tip cells and stalk cells. ALK1 syn-
ergises with Notch in stalk cells to induce expression of the
Notch targets HEY1 and HEY2 and thereby represses tip
cell formation and angiogenic sprouting. The ALK1-Fc
soluble protein fusion has entered clinic trials as a thera-
peutic strategy to sequester the high-affinity extracellular
ligand BMP9. Here, we determined the crystal structure of
the ALK1 intracellular kinase domain and explored the
effects of a small molecule kinase inhibitor K02288 on
angiogenesis. K02288 inhibited BMP9-induced phosphor-
ylation of SMAD1/5/8 in human umbilical vein endothelial
cells to reduce both the SMAD and the Notch-dependent
transcriptional responses. In endothelial sprouting assays,
K02288 treatment induced a hypersprouting phenotype
reminiscent of Notch inhibition. Furthermore, K02288
caused dysfunctional vessel formation in a chick chorioa-
llantoic membrane assay of angiogenesis. Such activity
may be advantageous for small molecule inhibitors cur-
rently in preclinical development for specific BMP gain of
function conditions, including diffuse intrinsic pontine
glioma and fibrodysplasia ossificans progressiva, as well as
more generally for other applications in tumour biology.
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Introduction
The Notch and ALK1 signalling pathways play critical roles
in the vasculature as evidenced by their respective linkage
to the diseases Alagille syndrome [1] and hereditary
haemorrhagic telangiectasia (HHT) [2]. Angiogenic stimuli
such as VEGF induce quiescent endothelial cells to spe-
cialise into tip cells that migrate towards the stimulus and
into attached stalk cells that proliferate behind for lumen
formation. Dll4 expression on tip cells allows for the
binding and activation of Notch receptors on adjacent stalk
cells triggering the release of the Notch intracellular domain
(NICD) for transcriptional activation. This signalling is
critically required for lateral feedback inhibition, which
blocks adjacent tip cell formation and therefore limits the
number of extending filopodia [3, 4]. Recent work has
highlighted a co-dependence on the type I BMP/TGF-b
receptor kinase ALK1 [5, 6]. ALK1 signals via phosphor-
ylation of the transcription factors SMAD1/5/8, which act
synergistically with NICD to induce the expression of
Notch target genes, including HEY1 and HEY2.
Overexpression of Dll4 reduces neo-angiogenesis, but
also differentiates vessels and downregulates VEG-
FR2 causing tumour resistance to anti-VEGF therapies [7].
Conversely, anti-Dll4 antibodies or gamma-secretase
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inhibitors that block Notch activation induce non-produc-
tive hypersprouting and reduce tumour growth [8, 9].
Targeting of ALK1 signalling has also generated signifi-
cant interest as an anti-angiogenic therapy. Clinical trials
are investigating anti-ALK1 antibodies, as well as soluble
ALK1-Fc protein, which acts to sequester the receptor’s
high-affinity ligand BMP9 [10].
In parallel, small molecule inhibitors of BMP signalling are
being developed against the closely related kinase ALK2.
Activating mutations in the intracellular domain of ALK2 are
associated with the musculoskeletal disorder fibrodysplasia
ossificans progressiva (FOP) [11] as well as the childhood
cancer diffuse intrinsic pontine glioma (DIPG) [12–15]. We
recently reported a 2-aminopyridine compound, K02288, that
exhibited low nanomolar affinity for both ALK1 and ALK2,
whilst retaining significant selectivity against the wider
human kinome [16]. In contrast to dorsomorphin and LDN-
193189, the inhibitor K02288 does not bind to the receptor
kinase VEGFR2 and therefore forms a valuable tool to explore
the effects of small molecule BMP inhibition in the endo-
thelium. Here, we show that K02288 can inhibit BMP9-ALK1
signalling in human umbilical vein endothelial cells (HU-
VECs) and block the induction of both BMP9 and Notch-
dependent target genes. As a result, K02288 induced a hy-
persprouting phenotype in 3D culture and caused dysfunc-
tional vessel formation in an advanced CAM model of
angiogenesis. Targeting ALK1 in angiogenesis may be syn-
ergistic with ALK2-targeted therapies which aim to address
tumour growth or ectopic bone formation.
Materials and methods
Antibodies, recombinant proteins and chemicals
BMP9 was obtained from PeproTech and used at a final
concentration of 1 or 10 ng/mL. Recombinant Dll4 was
obtained from R&D Systems. Antibodies against SMAD1
(#9743), P-SMAD1/5/8 (#9511) and P-SMAD2 (#3101) were
obtained from cell signalling. LDN-193189 was a kind gift
from Dr Paul Yu (Harvard). K02288 was purchased from
Biofocus and used at 1 lM. Soluble ALK1-Fc was purchased
from R&D Systems and used at 100 ng/mL. The gamma-
secretase inhibitor dibenzazepine (DBZ) was obtained from
Calbiochem and used at 10 nM. The gamma-secretase
inhibitor DAPT (N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-
phenyl]glycine-1,1-dimethylethyl ester) was obtained from
Tocris and used at a final concentration of 10 lM.
Protein expression
Human ALK1 (UniProt P37023; residues 195–503) was
cloned into the vector pFB-LIC-Bse. Baculoviral
expression was performed in Sf9 insect cells. Cell pellets
were resuspended in 50 mM HEPES pH 7.5, 500 mM
NaCl, 5 mM imidazole and 5 % glycerol, supplemented
with protease inhibitor set V (Calbiochem). Cells were
lysed using a C5 high-pressure homogeniser (Emulsiflex).
Nucleic acids were removed from the soluble lysate using
DEAE-cellulose resin. ALK1 protein was purified using an
N-terminal hexahistidine tag and eluted from nickel-
Sepharose by a step-wise gradient of increasing imidazole
up to 250 mM in a buffer comprising 50 mM HEPES pH
7.5, 500 mM NaCl, 5 % glycerol and 0.5 mM Tris-(2-
carboxyethyl)phosphine (TCEP). The eluted protein was
cleaved with TEV protease and further purified by size
exclusion chromatography using a S200 HiLoad 16/60
Superdex column equilibrated in 50 mM Tris–HCl pH 7.5,
300 mM NaCl and 0.5 mM TCEP. The protein was then
concentrated to 10 mg/mL with an additional 2 % glycerol.
Structure determination
ALK1 protein was mixed with 1 mM LDN-193189 and
crystallised using the sitting drop vapour diffusion method.
Viable crystals were grown at 20 C mixing 200 nL protein
solution with 100 nL of a reservoir solution containing
16 % PEG3350, 0.2 M Na/KPO4, 5 % ethylene glycol and
2 % glycerol. On mounting, crystals were cryo-protected
with an additional 25 % ethylene glycol. Diffraction data
collected at Diamond Light Source beamline I24 were
processed with XDS [17] and scaled with SCALA [18].
The coordinates of ALK2 (PDB 3H9R) were used in
molecular replacement performed in Phaser [19]. The
structure was subjected to manual model building in COOT
[20] alternated with structure refinement in REFMAC [21],
and the final model was verified for its geometric correct-
ness with MolProbity [22]. Diffraction data and refinement
statistics are provided in Table 1.
Cell culture
HUVECs were obtained from Lonza, maintained in EGM2
(Lonza) and used for experiments between passage 3 and
passage 6. For sDll4-coated plates, six-well plates were
coated in 0.2 % gelatin (w/v) in PBS containing 1 lg/mL
sDll4 or BSA control and incubated at 4 C for 24 h before
use. Plates were warmed to 37 C and the coating solution
aspirated prior to seeding HUVECs. HUVECs were treated
for 30 min with chemical inhibitor or vehicle control
before addition of BMP9. Cells were collected after 60 min
for Western blot analysis or 4 h for qPCR analysis.
Where indicated, HUVECs were also grown on uncoa-
ted plates. These cells were treated with BMP9 alone or
with BMP9 that was pre-incubated for 30 min with ALK1-
Fc. Additionally, on some plates, HUVECs were starved
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for 6 h in low serum medium (EGM2 without foetal bovine
serum). Complete medium was then added in the presence
or absence of indicated inhibitors. Cells were harvested
45 min after treatment and analysed by Western blot.
Transfections and dual luciferase assays
HUVECs were transfected with 800 ng RBPJ luciferase
construct and 200 ng Renilla luciferase in a 10-cm dish
using lipofectamine LTX reagent (Life Technologies).
After 24 h, cells were replated in low serum medium in
24-well plates coated with sDll4 or BSA. Cells were
allowed to attach for 5 h, K02288 added for 30 min and
10 ng/mL BMP9 added for a further 16 h. Dual luciferase
assays were performed according to the manufacturer’s
protocol (Promega).
Western blotting
Cells were harvested and lysed in 20 mM Tris–HCl pH 7.5,
150 mM NaCl, 1 % Triton X-100, 25 mM NaF and pro-
tease inhibitors (Roche) on ice for 30 min. Protein con-
centration was determined by BCA assay (Pierce) and
15 lg run on 4–12 % Bis–Tris gel (Life Technologies).
The protein was transferred onto PVDF membrane (GE
Healthcare) and probed with the relevant antibody at 4 C
overnight. Protein bands were detected using ECL (Pierce)
and an LAS4000 image reader.
RNA prep and quantitative PCR
Total RNA was prepared using Trizol (Invitrogen) fol-
lowing the manufacturer’s instructions. Two micrograms
of total RNA was converted to cDNA using Superscript III
reverse transcriptase (Invitrogen). Triplicate wells were
subjected to comparative quantitative PCR using SensiMix
SYBR Low-ROX (Bioline) and gene-specific primers.
Expression levels were normalised to GAPDH and relative
dRn to UT sample calculated. Experiments were repeated
at least three times, and error bars represent SEM. Primer
sequences for qPCR are provided in Table 2.
Sprouting assays
HUVEC were grown as spheroids (500 cells/spheroid) and
embedded in a fibrin gel as described by Nakatsu et al.
[23]. K02288 or ALK1-Fc was added on top of the gel in
EGM-2 media. The media was changed every 2 days.
Quantification of sprout number and length was made
2 days after addition of inhibitor and images acquired after
a further 4 days of treatment. Experiments were repeated at
least three times, and error bars represent SEM.
Table 1 Data collection and refinement statistics
Complex ALK1-LDN193189
PDB accession code 3MY0
Data Collection
Beamline Diamond light source, I24
Wavelength (A˚) 0.9779
Resolutiona (A˚) 58.96–2.65 (2.79–2.65)
Spacegroup P 32
Cell dimensions a = b = 118.8, c = 510.8 A˚
a = b = 90.0, c = 120.0
No. unique reflectionsa 233,884 (34,027)












RMS deviation bond (A˚) 0.012




RMS root mean square
a Values in brackets show the statistics for the highest-resolution
shells
b P/L/O indicate protein, ligand molecules presented in the active
sites and other (water and solvent molecules), respectively
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CAM assays
Fertilised chicken eggs (Henry Stewart & Co. Ltd) were
incubated at 37 C with a relative air humidity of 65 %. On
embryo development day 3 (EDD 3), a hole of approxi-
mately 3 mm in diameter was opened in the eggshell, and
on EDD 6, the hole in the shell was extended to a diameter
of approximately 3 cm. A polyethylene ring was deposited
on the CAM and 100 lL of either K02288, ALK1-Fc or
PBS was pipetted inside the ring. After 4 more days (EDD
10), the vessels were visualised under a microscope and
representative pictures acquired.
All experiments adhered to human and animal rights.
Results
Structural basis for small molecule inhibition of ALK1
To date, structural investigations of the BMP receptors and
their small molecule inhibitor binding have focussed on
ALK2 [16, 24, 25]. To characterise the homologous
structure of human ALK1, we expressed various deletion
constructs in Sf9 insect cells and purified the resulting
proteins for crystallisation trials. Viable crystals were
obtained in the presence of LDN-193189 using a construct
comprising ALK1 residues 195–503. The resulting struc-
ture was refined at 2.65 A˚ resolution and defines the kinase
domain as well as seven residues from the N-terminal GS
domain (Fig. 1a).
Overall, ALK1 adopts an inactive conformation of the
kinase domain that is closely conserved with ALK2 (root-
mean-square deviation 0.73 A˚ across 292 Ca atoms). The
co-crystallised inhibitor LDN-193189 is bound as expected
to the kinase hinge region with a single hydrogen bond to
His280 (Fig. 1b). Residues lining the inhibitor binding
pocket are strictly conserved between ALK1 and ALK2
explaining their common binding to small molecule BMP
inhibitors, including K02288 (Fig. 1c) [16]. By similarity
to the ALK2 co-structure (PDB 3MTF), K02288 is
expected to bind ALK1 in an ATP-mimetic fashion with
two hydrogen bonds to the kinase hinge (Fig. 1c). The
trimethoxyphenyl specificity group occupies the central
hydrophobic region and may hydrogen bond directly with
the catalytic b3 lysine, or via a water molecule as observed
in ALK2 (Fig. 1c) [16].
K02288 inhibits the BMP9-ALK1 pathway
To assess the ability of K02288 to inhibit BMP9-ALK1
signalling in HUVECs, we analysed the downstream
phosphorylation of SMAD1/5/8 by Western blot following
treatment with inhibitors or vehicle control. Addition of
K02288 reduced BMP9-induced P-SMAD1/5/8 levels,
whereas the gamma-secretase inhibitor dibenzazepine
(DBZ) had no effect (Fig. 2a). Stimulating HUVECs with
Dll4 to activate the Notch pathway resulted in an induction
in the levels of NICD that was reduced in the presence of
DBZ (Fig. 2a). However, Dll4 stimulation had no effect on
P-SMAD1/5/8 levels and did not interfere with the ability
of BMP9 to activate SMAD1/5/8 or with the ability of
K02288 to inhibit BMP9-induced P-SMAD1/5/8, suggest-
ing that K02288 is specifically inhibiting BMP9-ALK1
signalling (Fig. 2a). In HUVECs, BMP9 can also phos-
phorylate SMAD2 through heteromeric complexes of
ALK1/ActRII [26]. Again, K02288 was able to inhibit
BMP9-induced P-SMAD2 independently of the Notch
pathway (Fig. 2a). The established ligand trap ALK1-Fc
was also able to inhibit P-SMAD1/5/8 formation stimulated
by either BMP9 (Fig. 2b) or serum-rich complete medium
Fig. 1 Structural basis for inhibition of the ALK1 kinase domain.
a Ribbon representation of the ALK1 kinase domain highlighting the
different secondary structural elements. The co-crystallised inhibitor
LDN-193189 is bound to the hinge region in the ATP pocket. b Side
chain interactions involved in the binding of LDN-193189. c Model
for K02288 binding to ALK1 and ALK2. Shown is a superposition of
ALK1 and the ALK2 co-crystal structure with K02288 (PDB 3MTF)
[16]. A water molecule is shown for ALK2, whereas waters could not
be built in the ALK1 structure due to the lower resolution of this
structure
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(Fig. 2c). The latter was similarly inhibited by K02288, but
not by the gamma-secretase inhibitor DAPT (Fig. 2c).
We also analysed the effect of K02288 on BMP9-
induced gene expression using quantitative real-time PCR
(Fig. 2d–f). As expected, upregulation of the BMP-
response genes ID1 and SMAD6 was inhibited by K02288
similarly to the reduction observed in P-SMAD1/5/8
(Fig. 2d, grey bars). Additional stimulation of HUVECs
with Dll4 had minimal effect (Fig. 2d, black bars). In
contrast, maximal induction of the Notch-responsive genes
HEY1, HEY2 and JAG1 required combined stimulation
with both BMP9 and Dll4, consistent with the involvement
Fig. 2 K02288 inhibits BMP9-ALK1 signalling in HUVECs. a HU-
VECs were seeded onto BSA- or Dll4-coated plates and treated with
the indicated inhibitors and 10 ng/mL BMP9 for 1 h before collecting
and analysing by Western blot. b HUVECs on uncoated plates were
treated as indicated with 1 ng/mL BMP9 in the presence or absence of
100 ng/mL ALK1-Fc and similarly analysed by Western blot.
c HUVECs on uncoated plates were starved in low serum medium
(EGM2 without serum) for 6 h after which the medium was replaced
with complete EGM2 in the presence or absence of the indicated
inhibitors. Samples were analysed by Western blot. d–f Expression
levels of BMP-responsive (d), Notch-responsive (e) and tip cell-
specific (f) genes were determined in HUVECs seeded onto BSA- or
Dll4-coated plates, 4 h after treatment with 1 lM K02288 and 1 ng/
mL BMP9 (d) or 10 ng/mL BMP9 (e, f). g HUVECs were transiently
transfected with a RBPJ-responsive luciferase construct for 24 h, re-
plated onto BSA- or Dll4-coated plates in the presence or absence of
K02288 and luciferase activity determined after 24 h
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of both the P-SMAD1/5/8 and the NICD pathways
(Fig. 2e). K02288 treatment was effective at downregu-
lating all three genes under all conditions (Fig. 2e). The
expression of VEGFR1, a marker of tip cell specification,
was similarly upregulated by BMP9 and Dll4, whereas
VEGFR2 was unchanged or slightly reduced (Fig. 2f).
Again, K02288 treatment markedly reduced the ability of
both stimuli to induce VEGFR1 (Fig. 2f). Finally, to
exclude the possibility that K02288 inhibits Dll4-Notch
transcriptional activity via the co-activator RBPJ, we tested
the effect of K02288 in a RBPJ-responsive dual luciferase
reporter assay (Fig. 2g). As expected, there was no effect
of K02288 over a 100-fold concentration range. Together,
these data suggest that K02288 inhibits BMP and Notch
target gene expression by inhibiting the BMP receptor
ALK1 as well as ALK2.
K02288 induces a hypersprouting phenotype
in HUVECs
We next analysed the effects of K02288 in 3D culture
models of angiogenesis. We used a hanging drop assay in
which endothelial cells are collected as spheroids and
embedded in a fibrin gel. In this assay, treatment with
K02288 resulted in a hypersprouting phenotype (Fig. 3a),
with an increase in both the number and the length of
vessels formed after 2 days (Fig. 3b). Hypersprouting was
also observed upon treatment with ALK1-Fc, consistent
with the work of Larrive´e et al. [5] and in agreement with
the expected cooperation between BMP9 and Notch sig-
nalling [5, 6]. Interestingly, Cunha et al. [27] have also
reported an inhibitory effect of ALK1-Fc, perhaps reflect-
ing that sprouting is both a highly dynamic and context
dependent process.
K02288 causes dysfunctional angiogenesis in a chick
embryo CAM model
The hypersprouting effects induced by K02288 were
reminiscent of those observed upon disruption of the Notch
pathway [8], suggesting that K02288 increased tip cell
specification potentially resulting in dysfunctional vessel
formation. To assess whether K02288 may interfere with
angiogenesis in vivo, we used chick embryo chorioallan-
toic membrane (CAM) models which allow easy visual-
isation and quantification of angiogenesis. Again, the
effects of K02288 were similar to those observed with
ALK1-Fc (Fig. 4a). Two distinct phenotypes of disrupted
angiogenesis were observed with both treatments. A subset
of the treated CAM models displayed hypersprouting
Fig. 3 K02288 treatment
results in a hypersprouting
phenotype. a Endothelial
spheroids were embedded in a
fibrin gel and treated with either
1 lM K02288 or 100 ng/mL
ALK1-Fc. The vehicle DMSO
was used as a control. Ten
spheroids per condition were
photographed at 910
magnification on day 2 or day 6
after embedding (representative
examples are shown). b The
number and length of sprouts
were quantified on day 2 after
embedding using ImageJ
software. Experiments were
carried out at least three times,
and error bars represent SEM.
Data were analysed using a one-
way ANOVA; **p \ 0.01,
***p \ 0.001
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consistent with the 3D culture models. Moreover, shadows
and halos were observed around the angiogenic sprouts
suggestive of leaky dysfunctional vessels. A large fraction
of the CAM models exhibited a distinctive phenotype of
low vessel density reflecting the dysfunctional angiogene-
sis which occurs following hypersprouting (Fig. 4a). Thus,
the small molecule inhibitor K02288 has potential to
inhibit angiogenesis in vivo similarly to ALK1-Fc.
Discussion
Here, we show that a small molecule inhibitor targeting
intracellular BMP receptor domains can interfere with
angiogenesis in a similar fashion to ALK1-Fc and Notch
pathway inhibitors consistent with the known functional
synergy between these two signalling pathways (Fig. 4b).
Current pre-clinical development of small molecule BMP
inhibitors is directed primarily at ALK2 for treatment of
the skeletal malformation disorder FOP and more recently
the brain tumour DIPG. Both diseases are associated with
recurrent activating mutations in the ALK2 intracellular
domain that render the gain of function resistant to
endogenous biological inhibitors, including noggin. The
ATP pockets of the ALK1 and ALK2 kinase domains are
strictly conserved creating a significant challenge for the
design of chemical inhibitors that selectively target either
protein. Indeed, in drosophila, ALK1 and ALK2 are rep-
resented by a single ortholog, saxophone. However, angi-
ogenesis is a potentially critical process for the ectopic
bone formation characteristic of FOP, as well as the tumour
growth in DIPG. Therefore, the combined inhibition of
both receptors may have incremental benefits.
Whilst Notch inhibition has shown promising anti-
tumour activity, it is also associated with potential toxicity
[28], raising some concerns for the development of BMP
inhibitors that may similarly impact this pathway. BMP
signalling is also complex and pleiotropic with wide
ranging roles outside the vasculature in both development
and tissue repair. Nonetheless, such molecules appear to be
well tolerated in animals [25]. The availability of multiple
tool compounds and therapeutic strategies offers promise
to increase our understanding of vascular biology and the
hope to develop safe and effective new medicines.
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